Plain-English translation of NCT05997017 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing a combination of two medications — and letrozole — to see if they can help treat advanced or recurrent endometrioid endometrial cancer. is given by IV infusion twice per cycle, while letrozole is a daily oral pill. The goal is to learn whether this medication combination is effective and safe for patients whose cancer has spread or come back.
Currently, treatment options for advanced or recurrent endometrioid endometrial cancer are limited, especially for patients who have not had much prior chemotherapy. This trial exists to see if this new medication combination might offer a better option for controlling the cancer and improving outcomes.
You likely qualify if…
You likely don't qualify if…
If you join this trial, you will receive as an IV infusion on days 1 and 8 of each 21-day cycle, along with letrozole as a daily oral tablet. You will continue this treatment as long as it is helping your cancer and you are not experiencing unacceptable side effects. You will have regular clinic visits and imaging scans to monitor how you are responding to the medication and to check for any side effects.
AI-generated summary from trial data · Jun 4, 2026 · Not medical advice
United States